Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Durvalumab (Primary)
- Indications Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms POP-DURVA
Most Recent Events
- 08 Jul 2024 Planned number of patients changed from 195 to 200.
- 09 Dec 2023 Planned number of patients changed from 200 to 195, as per Trial design, presented at the 46th Annual San Antonio Breast Cancer Symposium
- 09 Dec 2023 Trial design, presented at the 46th Annual San Antonio Breast Cancer Symposium